Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8: early-phase trial registry

5 of 9 indexed Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8: 9 US clinical trials tracked, 5 recruiting.

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Emory University, running 3 of these trials.

Enrollment posture brief

Registry condition clinical-stage-iv-hpv-mediated-p16-positive-oropharyngeal-carcinoma-ajcc-v8

OPEN 5 | RECR 56% | LATE 1 | EARLY 6 | RANK #1916 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)

Clinical Stage IV HPV-Me (th…56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 research.

    Emory University accounts for 3 of 9 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 enrolment sits around 118 participants.

    Median target enrolment is 118 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.

  4. Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 31

Open and recent trials

9 total, page 1 of 1

RECRUITING 440 participants

Oropharynx (OPX) Biomarker Trial

Mayo Clinic

NCT06356272
RECRUITING Phase 2 150 participants

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

NCT05136196
RECRUITING NA 118 participants

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Emory University

NCT06662058
RECRUITING Phase 1 40 participants

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory University

NCT06868433
RECRUITING Phase 2 28 participants

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Emory University

NCT06636734
ACTIVE NOT RECRUITING Phase 2 430 participants

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

NCT05063552
ACTIVE NOT RECRUITING Phase 3 290 participants

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

ECOG-ACRIN Cancer Research Group

NCT05721755
ACTIVE NOT RECRUITING Phase 2 46 participants

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Marcelo Bonomi

NCT04862650
ACTIVE NOT RECRUITING Phase 1 7 participants

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

NCT04576091

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Top Sponsors

Emory University 3 trials
National Cancer Institute (NCI) 3 trials
Marcelo Bonomi 1 trials
ECOG-ACRIN Cancer Research Group 1 trials
Mayo Clinic 1 trials

Named interventions

Most-linked intervention names on Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Computed Tomography Procedure
5 trials
Biospecimen Collection Procedure
5 trials
Magnetic Resonance Imaging Procedure
4 trials
Carboplatin Drug
3 trials
Pembrolizumab Biological
2 trials
Elimusertib Drug
1 trials
Autologous Tumor Membrane Vesicles Vaccine Biological
1 trials
Lovastatin Drug
1 trials

US sites by state

Facility locations filed on Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 trials. A trial with sites in several states counts in each.

Georgia 4 trials
California 3 trials
Minnesota 2 trials
Illinois 2 trials
Florida 2 trials
Arkansas 2 trials
Utah 1 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Emory University sponsors the most Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See Emory University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 condition card totals 9 registered trials; most-linked intervention Computed Tomography; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.